NEW YORK (GenomeWeb News) – Becton Dickinson's BD Diagnostics segment today said that its BD Max Cdiff Assay has been cleared by the US Food and Drug Administration for marketing in the US.

The assay runs on the BD Max System and detects the toxin B gene, which has been implicated as a cause of disease in patients suspected of having Clostridium difficile. The assay was CE-marked in March 2012.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.

Mar
08
Sponsored by
Swift Biosciences

This webinar will discuss an optimized protocol for methyl-CpG binding domain sequencing (MBD-seq), which enables comprehensive, adequately powered, and cost-effective large-scale methylome-wide association studies (MWAS) of almost all 28 million CpG sites in the genome.

Apr
05
Sponsored by
Labcyte

This webinar will discuss how acoustic liquid handling can reduce the time and costs for labs performing carrier screening with next-generation sequencing.